Summary

for people ages 18-130 (full criteria)
at UCLA
study started
estimated completion

Description

Summary

This study is intended to provide access to CP-675,206 for patients who have previously received CP-675,206 in a clinical trial.

Official Title

A Rollover Protocol For Patients Who Received CP-675,206 In Other Protocols

Keywords

Colorectal Neoplasms Melanoma Prostatic Neoplasms Renal Cell Carcinoma Neoplasms Patients Who Have/Have Had Melanoma and Other Tumors Melanoma and other tumors Carcinoma, Renal Cell Tremelimumab Ipilimumab CP-675,206 (Tremelimumab)

Eligibility

You can join if…

Open to people ages 18-130

  • The subject must have already received CP-675,206 in another protocol
  • Females of childbearing potential must agree to practice a form of effective contraception for 12 months following any dose of study drug. The definition of effective contraception will be based on the judgement of the investigator.
  • Subject must be willing and able to provide written informed consent and to comply with scheduled visits and other trial procedures

You CAN'T join if...

  • None

Locations

  • Research Site
    Los Angeles California 90095 United States
  • Research Site
    Los Angeles California 90024 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
AstraZeneca
ID
NCT00378482
Phase
Phase 2
Study Type
Interventional
Last Updated